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Understanding the physiological processes underlying the ability of Mycobacterium abscessus 
to become a chronic pathogen of the cystic fibrosis (CF) lung is important to the development 
of prophylactic and therapeutic strategies to better control and treat pulmonary infections 
caused by these bacteria. Gene expression profiling of a diversity of M. abscessus complex 
isolates points to amino acids being significant sources of carbon and energy for M. abscessus 
in both CF sputum and synthetic CF medium, and to the bacterium undergoing an important 
metabolic reprogramming in order to adapt to this particular nutritional environment. Cell 
envelope analyses conducted on the same representative isolates further revealed unexpected 
structural alterations in major cell surface glycolipids known as the glycopeptidolipids 
(GPLs). Besides showing an increase in triglycosylated forms of these lipids, CF sputum- and 
synthetic CF medium-grown isolates presented as yet unknown forms of GPLs representing 
as much as 10 to 20% of the total GPL content of the cells, in which the classical amino 
alcohol located at the carboxy terminal of the peptide, alaninol, is replaced with the 
branched-chain amino alcohol, leucinol. Importantly, both these lipid changes were 
exacerbated by the presence of mucin in the culture medium. Collectively, our results reveal 
potential new drug targets against M. abscessus in the CF airway and point to mucin as an 
important host signal modulating the cell surface composition of this pathogen.  
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The Mycobacterium abscessus complex (MABSC) is a group of opportunistic rapidly growing 
mycobacteria comprised of three subspecies, Mycobacterium abscessus subsp. abscessus (Mabs), 
Mycobacterium abscessus subsp. massiliense (Mmas), and Mycobacterium abscessus subsp. 
bolletii, that can cause an array of clinical diseases in human including lung, skin and soft tissue, 
central nervous system and disseminated infections. Recently, MABSC has become an important 
group of pathogens in the setting of CF lung disease1-3. Of particular concern are the results of 
detailed epidemiology and population-level whole genome sequencing studies indicating that 
dominant circulating clones of MABSC have emerged and are now present on every continent4-6.  
Understanding the complex physiological processes underlying the ability of MABSC to 
become a pathogen of the CF lung could provide valuable information on infection strategies of 
this organism and lead to innovative prophylactic and therapeutic strategies to better control and 
treat MABSC infections. One approach toward this goal has focused on analyzing the partial or 
whole genome sequence of serially-isolated strains from CF and non-CF patients to gain insight 
into the genetic basis of this adaptation6-8. These studies have highlighted a number of mutations, 
including those controlling the switching of MABSC from a smooth to rough morphotype, a 
process known to be related to the decrease or loss of production of surface glycopeptidolipids 
(GPLs) and to be associated with disease progression7-12. The functional significance of other 
mutations is not as well understood and may benefit from the availability of a well-defined culture 
medium mimicking the nutritionally complex CF lung environment in which the stepwise 
adaptation of MABSC to various host-relevant stresses could be studied.  
We here investigated how closely chemically defined synthetic CF medium (hereafter referred 
to as SCFM2)13 approximates the nutritional environment of actual CF sputum using a panel of 
genotypic and phenotypic read-outs. To this end, four Mabs and Mmas clustered (i.e., globally 
 3 
circulating) and non-clustered isolates from CF patients were grown in SCFM2 and their gene 
expression profile and cell envelope composition were compared to those of the same strains 
grown in standard laboratory medium (7H9-ADC-Tween 80) or in actual CF sputum. Our results 
indicate that while MABSC grows at similar rates and to similar high cell densities in SCFM2 as 
in 7H9-ADC-Tween 80, it varies significantly in terms of gene expression profile and cell envelope 
composition, with SCFM2 being a much closer mimic of actual CF sputum. Collectively, our 
analyses point to amino acids being major sources of carbon and energy under CF-relevant growth 
conditions and to their utilization by the bacterium further causing important changes in the cell 





Growth characteristics of MABSC isolates in SCFM2 -  Phenotypic and genotypic studies were 
conducted on both clustered (i.e., dominant, globally-circulating within the CF patient community) 
and non-clustered isolates of M. abscessus subsp. abscessus and M. abscessus subsp. massiliense, 
including strains with rough and smooth morphotypes. Mabs 1091 and Mmas 1239 are 
representative of dominant clades of Mabs and Mmas isolates whereas Mmas 184 and Mmas 604 
are phylogenetically unrelated to any major clusters6. Further, Mabs 1091 is a rough morphotype 
isolate while all other strains are smooth. Although our study was not powered to typify potential 
clustered vs non-clustered, Mabs vs Mmas, or rough vs smooth specific responses to growth 
conditions, this strain selection ensured broad representation of the adaptive response of MABSC 
isolates to CF airway sputum.  
As a first step toward characterizing the physiological response of MABSC to exposure to 
synthetic or actual CF sputum, we examined and compared the planktonic growth of the isolates 
in SCFM2, 7H9-ADC-Tween-80 and 20% CF sputum diluted in minimal M63 medium. All 
isolates grew to high cell density in SCFM2 with doubling times (~ 4.32 to 4.96 hours depending 
on the isolate) comparable to those observed in 7H9-ADC-Tween-80 (~ 4.70 to 4.94 hours) [Figure 
1 and Figure S1].  
 
 
Figure 1: Growth characteristics of isolate Mmas 1239 at 37°C in 7H9-ADC-Tween-80, complete 
SCFM2 medium, CF sputum (diluted 20% in minimal M63 medium) and M63 medium 
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Growth in CF sputum, in contrast, was significantly slower and characterized by a long lag period 
followed by a period of slow replication (doubling time of ~ 18 days for Mmas 1239) [Figure 1]. 
Given that Pseudomonas aeruginosa grows as proficiently in 10% CF sputum and earlier 
generation synthetic CF medium14-15, this result is suggestive of the likely superior competitiveness 
of P. aeruginosa over MABSC during polymicrobial growth in CF sputum.  
 
Increased production of triglycosylated and branched amino alcohol-containing forms of 
glycopeptidolipids by MABSC grown in SCFM2 and actual CF sputum - The unique cell 
envelope of mycobacteria is known to play important roles in the modulation of the innate and 
adaptive immune responses and in the resistance of mycobacterial pathogens to the bactericidal 
mechanisms of the host16. Surface GPLs in particular, which in the fast-growing nontuberculous 
Mycobacterium, M. smegmatis, have been shown to represent up to 85% of the surface-exposed 
lipids of the bacilli17, govern to a large extent the rough or smooth morphotype and planktonic vs 
biofilm growth of MABSC, and have been implicated in a number of virulence traits characterizing 
this microorganism9,11,18-27. To determine whether the nutritional environment of CF airway 
sputum might affect the GPL composition of MABSC, the total lipids from Mmas isolates 1239, 
184 and 604 grown to exponential phase in 7H9-ADC-Tween-80 and in complete SCFM2 were 
analyzed by liquid chromatography-mass spectrometry (LC-MS). Included in these analyses were 
the same three isolates grown in SCFM2 medium devoid of mucin, since host mucin glycans have 
been shown to regulate the cell surface properties and secretion of a number of virulence factors 
in the CF pathogen, P. aeruginosa28. For comparison, Mmas isolate 1239 was also cultured in 10% 
CF sputum diluted in minimal M63 medium and in M63 containing 0.2% glucose as sole carbon 
source. The Mabs isolate 1091 which displays a rough morphotype and is essentially devoid of 
GPLs [Figure S2] was not included in this experiment.  
LC-MS analysis of GPLs produced by the three Mmas isolates revealed the expected presence 
of diglycosylated and triglycosylated forms of these lipids in all strains. In general terms, MABSC 
diglycosylated GPLs consist of a tripeptide aminoalcohol (D-Phe- D-allo-Thr- D-Ala-L-alaninol) 
N-linked to a long (C26 to C34) 3-hydroxylated or 3-methoxylated fatty acyl chain, and substituted 
on the allo-Thr residue by a 3,4-O-diacetylated 6-deoxytalosyl unit, and on the terminal L-alaninol 
residue by a 3,4-di-O-methyl rhamnosyl unit29 [Figure 2A]. In the triglycosylated forms, the 3,4-
di-O-methyl-rhamnosyl unit is further glycosylated with a rhamnosyl unit at position 2 [Figure 
2D]. Interestingly, a growth medium-dependent change in the relative proportion of tri- to di-
glycosylated GPLs was noted in all three isolates. This ratio increased 3.55-, 3.38- and 3.43-fold 
in Mmas 1239, 184 and 604 grown in complete SCFM2 relative to SCFM2 devoid of mucin, 
respectively [Figure 3A]. The ratios measured in 7H9-ADC-Tween-80 were intermediate between 
that measured in SCFM2 with and without mucin but much closer to the ratio measured in SCFM2 
without mucin in two out of the three isolates. Importantly, a 1.86-fold increase in tri- relative to 
di-glycosylated GPLs was also observed in Mmas 1239 grown in 10% CF sputum relative to M63-
glucose [Figure 3A]. Collectively, these results are suggestive of the hyper-glycosylation of GPLs 





Figure 2: Structures of some of the major forms of GPLs produced by Mmas 1239, Mmas 184, and 
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(A) MS/MS spectrum of the most abundant GPL with a molecular weight of 1234 Da containing a 2-
methoxy C28 fatty acyl residue, a di-O-acetyl 6-deoxytalosyl residue (attached to the allo-threonine 
residue), and a 3,4 di-O-methyl rhamnosyl residue attached to the alaninol residue. The ion at m/z 556 
shows the weight of the fatty acyl (2-methoxy C28 fatty acyl) substituent as attached to the phenylalanine. 
The ion at m/z 831 where both sugars have been eliminated shows the molecular weight of the entire 
acylated peptide and is consistent with the usual amino acids found in GPLs: phenylalanine, allo-threonine, 
and alanine) and the amino alcohol (alaninol) as shown in the figure. The sequence of the peptide is shown 
by the cleavages at the carbonyl carbons (B ions) at m/z’s 584, 915, and 986. The ion at m/z 1061 where the 
glycosyl residue attached to alaninol is lost shows the presence of two O-acetyl groups on the 6-
deoxytalosyl residue. Also, this ion in combination with the M+H ion at m/z 1235 shows that the residue 
lost from the alaninol is the di-O-methyl rhamnosyl residue.  
(B) The MS/MS spectrum of the GPL at m/z 1248 shows that the amino alcohol at the carboxy terminal of 
the peptide is 28 amu higher in molecular weight than alaninol. In this GPL, the ion at m/z 542 shows the 
presence of a 2-hydroxyl C28 fatty acyl component as it is 14 amu lower than the corresponding ion in 
panel (A), but the ion for the acylated peptide without the glycosyl components at m/z 845 is 14 amu higher 
than that in panel (A) showing that the peptide itself is 28 amu higher than expected. The B ions at m/z’s 
570, 901 and 972 are consistent with the expected phenylalanine, allo-threonine and alanine showing that 
the extra 28 amu are on the amino alcohol unit. All the other ions in the spectrum (as discussed for panel 
A) are consistent with this assignment. Since our analysis of amino alcohols showed the presence of valinol 
(see Figure S2), we conclude that, in this GPL, valinol has been substituted for alaninol.  
(C) MS/MS spectrum for the GLP with a molecular weight of 1276 Da which goes up in mucin-containing 
media (see Figure 3B). Analysis of the spectrum using the m/z values of the same cleavages discussed above 
for panels (A) and (B) shows that this GPL contains a 2-methoxy C28 fatty acyl group and that the amino 
alcohol is 42 amu heavier than alaninol. Since our analysis of amino alcohols showed the presence of 
leucinol (see Figure S2), we conclude that, in this GPL, leucinol has been substituted for alaninol.  
(D) The MS/MS of a triglycosyl GPL with a molecular weight of 1380 Da which increased 1.6 to 2.1 fold 
in all three isolates grown in complete SCFM2 medium relative to SCFM2 without mucin (see Figure 3A) 
shows the presence of alaninol residue in the peptide, a 2-methoxy C28 fatty acyl group, and two O-acyl 
groups on the 6-deoxytalosyl residue. The ion at m/z 1225 in conjunction with the M+H ion at m/z 1381 
shows that a non-methylated rhamnosyl residue is attached to a 3,4-di-O-methyl rhamnosyl residue which, 
as shown by the ion at m/z 1061, is attached to the alaninol residue. 
 
Another intriguing observation that resulted from these analyses was the detection by LC-
MS/MS of previously unreported forms of GPLs differing from the canonical forms described in 
Figure 2 A and D by the nature of their carboxy terminus aminoalcohol [Figure 2B-C]. Figure S3 
presents gas chromatography-mass spectrometry (GC-MS) evidence for the branched-chain amino 
alcohols, valinol or leucinol, indeed replacing the prototypical alaninol in predominant forms of 
these atypical GPL species identified in all isolates. While these atypical forms of GPLs were 
found in all isolates independent of the culture medium, the production of one of them - a 
diglycosylated leucinol-containing form with m/z 1276 [Figure 2C] - increased sharply (1.8 to 3.4-
fold) in all three strains grown in complete SCFM2 relative to SCFM2 without mucin, representing 
as much as 8.8 to 23.6% of total GPLs in the SCFM2-grown cells and 9.5% of total GPLs in CF 
sputum-grown Mmas 1239 [Figure 3B]. The abundance of this GPL species was 5.8 to 8.4-fold 
greater in strains grown in complete SCFM2 relative to 7H9-ADC-Tween-80 and also increased 
1.5-fold in Mmas 1239 grown in 10% CF sputum relative to M63-glucose [Figure 3B]. Changes 
in other GPL forms were either not consistent across isolates, or not SCFM2-dependent, or not 
recapitulated in 10% CF sputum. Collectively, these findings indicate that MABSC undergoes 
significant cell surface remodeling under CF-relevant growth conditions and that mucin plays a 




Figure 3: Changes in the GPL content of MABSC isolates grown in SCFM2 complete medium and 
in CF sputum. (A) Mucin-dependent increase in the ratio of tri- to di-glycosylated GPLs. Di- to tri-
glycosylated GPL ratios in Mabs 1239, Mmas 184 and Mmas 604 grown in SCFM2, SCFM2 without mucin, 
7H9-ADC-Tween-80, 10% CF sputum or M63-glucose are expressed relative to the ratio measured in the 
strains grown in 7H9-ADC-Tween-80 arbitrarily set to 1. Two independent batches of 7H9-ADC-Tween-
80 and SCFM2 (with and without mucin)-grown Mmas 1239 were analyzed and averages and standard 
deviations are shown. Asterisks denote statistical significance per Student’s t-test (p<0.05).  
(B) Build-up of a leucinol-containing form of diglycosylated GPL in MABSC isolates grown in SCFM2 
complete medium and in 10% CF sputum. Evidence for the accumulation of a diglycosylated form of GPL 
with m/z 1276 in Mabs 1239, Mmas 184 and Mmas 604 grown in complete SCFM2 and 10% CF sputum 
relative to 7H9-ADC-Tween-80 and SCFM2 lacking mucin. The percentage abundance of this GPL form 
in each isolate and each medium relative to total GPLs is indicated beneath the graph. The “total” GPL 
content of the cells was calculated using the 26 most abundant forms of these lipids which collectively were 
estimated to represent > 85% of the GPL content of all isolates.  
Other cell envelope analyses conducted on the isolates grown in the different media, including 
total (glyco)lipid content [Figure S4A and LC-MS data not shown], monosaccharide content of 
extractable lipids and delipidated cells [Table S1], and mycolic acid composition [Figure S4B] 




















































































































































































































Transcriptional profiling of MABSC grown in 7H9-ADC-Tween-80 versus actual and synthetic 
CF airway sputum reveals extensive metabolic reprogramming related to amino acid utilization 
-  Transcriptional profiling of the four MABSC clinical isolates grown to exponential phase in 
7H9-ADC-Tween 80, SCFM2 complete medium or 20% CF sputum was next performed using 
RNA-sequencing to investigate the most significant changes in physiology between MABSC 
grown in classical 7H9-ADC-Tween 80 laboratory medium and SCFM2, and to determine how 
closely SCFM2 mimics the physiological state of MABSC in actual patient sputum. For each 
isolate, genes were identified that showed ≥2 Log2 fold-change in expression between culture 
conditions with a false discovery rate adjusted p-value ≤0.05. Isolates were further compared 
between them for common differentially regulated genes. Owing to the limited quantities of patient 
sputum available for these studies, gene expression profiling in 20% sputum was only performed 
on the clustered Mmas isolate 1239.  
The number and lists of genes differentially expressed in the different culture conditions for 
each isolate are presented in Figure 4A and Tables S2A-E. In all isolates, there were more genes 
expressed at a higher level in SCFM2 compared to 7H9-ADC-Tween 80 than there were genes 
expressed at a lower level. Twenty-six genes were expressed at higher level in all four isolates in 
SCFM2 relative to 7H9-ADC-Tween 80 [Tables S2A-D]. Given the strong overlap in gene 
expression profiles between isolates, a strain independent response to media was calculated by 
pooling all SCFM2 samples and all 7H9-ADC-Tween 80 samples from all four isolates for 
differential expression analysis. In this analysis, 60 genes had significantly higher expression in 
SCFM2 than 7H9-ADC-Tween 80 and 21 genes were expressed at significantly lower level in 
SCFM2 [Table 1].  
 
 
Figure 4: Transcriptional response of MABSC to SCFM2 and actual CF sputum.  
(A) Number of genes in each isolate expressed at higher or lower level in SCFM2 when compared to 7H9-
Comparison Up-regulated Down-regulated 
1239 SCFM2 vs 7H9 97 53 
184 SCFM2 vs 7H9 58 13 
604 SCFM2 vs 7H9 81 31 
1091 SCFM2 vs 7H9 189 118 
All 4 isolates pooled SCFM2 
vs 7H9 60 21 
1239 CF sputum vs SCFM2 219 151 
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ADC-Tween 80, or in CF sputum when compared to 7H9-ADC-Tween 80 or SCFM2. Most divergent from 
other isolates was Mabs 1091 which displayed the highest number of both up- and down-regulated genes 
in SCFM2 compared 7H9-ADC-Tween 80 [see Table S2D]. It is unclear at this point whether the 
differentially expressed genes unique to this isolate are the result of its rough morphotype or related to the 
different MABSC subspecies or clone to which it belongs. 
(B) Heatmap showing the Log2 fold-change of Mmas 1239 transcripts in SCFM2 and CF sputum relative 
to 7H9-ADC-Tween 80.  
(C) Venn diagrams showing number of genes expressed at significantly higher or lower level in Mmas 1239 
in CF sputum and SCFM2 compared to 7H9-ADC-Tween 80. The complete list of these genes is provided 
in Table S2F.  
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Table 1: List of genes that were expressed at higher or lower levels in SCFM2 than in 7H9-ADC-Tween 80, independent of MABSC isolate. 
More or less highly expressed genes in SCFM2 were defined as ≥2 Log2 fold-change in expression compared to cells grown in 7H9-ADC-Tween 80, 
with a false discovery rate adjusted p-value (padj) <0.05. Base mean is the mean of the gene counts in SCFM2- and 7H9-ADC-Tween 80-grown 
bacteria. Genes in bold were found to be similarly differentially regulated in CF sputum relative to 7H9-ADC-Tween 80 (see Table S2F). Similarly 
colored genes denote gene clusters.  





Pooled SCFM2 vs 7H9-ADC-Tween 80 upregulated genes 
 MSF transporter MAB_0069   Major facilitator family transporter 620 2.6 6.97E-09 
 - MAB_0304  Hypothetical protein 86 3.2 0.001599021 
 Protein chaperone MAB_0650 groEL2 60 kDa chaperonin 2 (Protein Cpn60 2) 109891 2.5 5.96E-27 
 - MAB_1030  Hypothetical protein 3617 2.0 0.000297421 
  MAB_1184c  Putative transcriptional regulator, MarR family 816 2.5 5.68E-19 
 Amino acid metabolism MAB_1185c  Probable enoyl-CoA hydratase 3400 2.4 2.04E-23 
 (Val catabolism) MAB_1186c mmsB 3-hydroxyisobutyrate dehydrogenase 2234 2.4 1.20E-29 
  MAB_1187c  Probable enoyl-CoA hydratase 3550 2.5 8.73E-31 
  MAB_1188c  Probable acyl-CoA dehydrogenase 2952 3.7 4.55E-27 
  MAB_1189c mmsA Probable methylmalonic acid semialdehyde dehydrogenase 4478 3.2 3.92E-40 
 Amino acid metabolism MAB_1330 rocA 1-pyrroline-5-carboxylate dehydrogenase 32153 3.8 1.27E-111 
 (Arg and Pro catabolism) MAB_1331  Probable proline dehydrogenase 10679 3.8 1.72E-172 
  MAB_1332 fadD Probable fatty-acid-CoA ligase FadD 2905 2.1 1.83E-44 
  MAB_2122 mbtE Putative peptide synthetase 462 2.1 1.93E-12 
 Mycobactin synthesis MAB_2248 mbtE Probable peptide synthetase 236 2.0 3.88E-08 
  MAB_2249 mbtG Probable lysine-N-oxygenase 168 2.0 2.99E-09 
 MSF transporter MAB_2273  Putative MFS transporter 1024 2.4 1.00E-80 
 Amino acid metabolism MAB_3100 ald L-alanine dehydrogenase 45451 5.4 1.10E-40 
 (Ala catabolism) MAB_3101c  Hypothetical protein – putative reductase 11584 5.1 5.50E-118 
 - MAB_3153c  Hypothetical protein 68 2.8 7.23E-15 
  MAB_3154c  Hypothetical protein 165 2.8 1.64E-24 
 - MAB_3180  Hypothetical membrane protein 103 3.1 1.87E-74 
 Amino acid transport MAB_3369  Putative integral membrane amino acid transport protein 402 3.0 1.52E-22 
 - MAB_3385  Hypothetical protein – putative transcriptional regulator 788 3.7 3.56E-13 
  MAB_3386c  Hypothetical membrane protein 1388 4.2 1.30E-20 
 - MAB_3438  Putative short-chain dehydrogenase/reductase 129 2.7 0.035324512 
 Protein chaperone MAB_3467c  18 kDa antigen (HSP 16.7) 6073 3.0 3.11E-18 
 - MAB_3617  Hypothetical protein 411 2.3 1.64E-23 
  MAB_3645  Putative reductase 2202 5.4 2.88E-30 
 Amino acid metabolism MAB_3646c lat L-lysine aminotransferase 32693 7.9 6.83E-41 
 (Lys catabolism) MAB_3647c lprA Probable AsnC transcriptional regulatory protein 3836 3.5 4.24E-22 
  MAB_3648  Hypothetical protein 6468 5.9 2.53E-31 
  MAB_3649 pcd Probable piperideine-6-carboxylate dehydrogenase 22782 5.8 4.43E-33 
  MAB_3650  Putative TetR-family transcriptional regulator 2276 3.2 2.30E-16 
 Protein chaperones MAB_3731c groEL1 60 kDa chaperonin 1 6834 2.0 2.91E-12 
  MAB_3732c groES 10 kDa chaperonin 59928 2.1 7.43E-15 
 - MAB_3762  Hypothetical protein 959 3.1 2.84E-23 
 Amino acid metabolism MAB_3840  Amidinotransferase family protein 6816 7.2 5.72E-157 
 (Arg catabolism) MAB_3841 rocD1 Ornithine aminotransferase 4795 5.9 1.15E-76 
  MAB_3842 rocE Probable arginine permease (integral membrane protein) 3592 2.1 1.12E-17 
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 Protein chaperone MAB_4402  Heat shock protein Hsp20 288 2.3 1.08E-05 





Pooled SCFM2 vs 7H9-ADC-Tween 80 upregulated genes (continued) 
 Peroxynitrite reductase/ MAB_4407c ahpD Putative alkylhydroperoxidase 880 3.0 2.34E-28 
 peroxidase MAB_4408c ahpC Putative alkylhydroperoxidase C 1550 2.4 5.76E-30 
 Amino acid metabolism MAB_4538c fadE Putative acyl-CoA dehydrogenase 2341 4.2 1.81E-136 
 (Leu catabolism) MAB_4539c accA Putative acyl-CoA carboxylase alpha subunit 2315 4.5 4.45E-137 
  MAB_4540c accD Putative methylcrotonoyl-CoA-carboxylase 1981 4.6 7.90E-138 
 Amino acid metabolism (Met) MAB_4623c  5-methyltetrahydropteroyltriglutamate--homocysteine S-methyltransferase 2569 2.4 1.44E-07 
 - MAB_4735  Putative starvation-induced DNA protecting protein/Ferritin and Dps 163 2.2 0.000500508 
  MAB_4742c  Putative methyltransferase 14035 5.1 5.60E-80 
 - MAB_4743c  Putative dehydrogenase/reductase 33256 7.6 4.70E-198 
  MAB_4744c  DsbA-like thioredoxin domain protein 14307 8.0 7.85E-187 
  MAB_4745 mmpS Putative membrane protein 2277 7.8 1.07E-143 
  MAB_4746 mmpL Putative membrane protein 15104 8.1 9.78E-97 
  MAB_4747  Putative copper-sensing transcriptional repressor 5091 4.4 1.19E-82 
  MAB_4748c  Putative pyridoxamine 5'-phosphate oxidase 1406 4.0 4.14E-53 
  MAB_4915c  Hypothetical protein – PknH-like extracellular domain protein 458 3.5 1.55E-134 
 Amino acid metabolism MAB_4916c bkdC Probable branched-chain keto acid dehydrogenase E2 component 8541 4.4 6.15E-116 
 (catabolism of branched MAB_4917c bkdB Probable branched-chain keto acid dehydrogenase E1 component, beta subunit  4900 4.0 6.13E-19 
 amino acids, Val, Leu, MAB_4918c bkdA Probable branched-chain keto acid dehydrogenase E1 component, alpha subunit  6217 3.8 1.20E-12 
 Ile) MAB_4919   Putative transcriptional regulator, AsnC family 237 2.2 9.98E-18 
       





Pooled SCFM2 vs 7H9-ADC-Tween 80 downregulated genes 
 - MAB_0741c  Hypothetical protein 750 -2.4 4.62E-18 
 Manganese transport MAB_1031c mntH Probable manganese transport protein MntH 2211 -3.4 1.22E-26 
 Amino acid metabolism MAB_1661c cysH Phosphoadenosine phosphosulfate reductase (CysH) 940 -2.1 2.24E-17 
 (Cys biosynthesis) MAB_1662c  Probable sulfite reductase [ferredoxin] 2127 -2.4 8.11E-58 
 Cytochrome P450 MAB_2048c  Probable cytochrome P450 8405 -2.5 0.033135945 
 Amino acid metabolism MAB_2165  Probable acetolactate synthase, large subunit 145 -2.4 8.93E-11 
 (Val and Ile biosynthesis) MAB_2166  Hypothetical protein 294 -2.1 2.41E-08 
 - MAB_2551  Hypothetical protein 204 -2.2 2.80E-17 
  MAB_2599  Hypothetical protein 153 -2.2 8.07E-26 
 - MAB_2600  Hypothetical protein 160 -2.0 6.02E-34 
  MAB_2601  Hypothetical protein 250 -2.4 2.90E-22 
 - MAB_2693  Hypothetical protein 322 -6.0 3.90E-24 
  Amino acid metabolism MAB_2791c  Putative ethanolamine permease 581 -2.2 8.67E-06 
 and transport? MAB_2792c  Probable aldehyde dehydrogenase 1088 -2.7 8.97E-08 
 - MAB_3359c  GCN5-related N-acetyltransferase 454 -2.2 0.000366436 
 Amino acid metabolism MAB_3687 metC Probable O-acetylhomoserine sulfhydrylase MetC (homocysteine synthase) 1664 -2.2 4.33E-21 
 (Met biosynthesis) MAB_3688 metA Homoserine O-acetyltransferase 1230 -2.2 3.71E-108 
  MAB_3689  Putative methyltransferase 362 -2.2 2.18E-111 
 - MAB_3903  Hypothetical protein (nitroreductase?) 7602 -2.2 0.041104308 
 Cytochrome P450 MAB_4456  Putative cytochrome P450 708 -2.1 3.46E-12 
 - MAB_4715c   Conserved hypothetical protein 2782 -4.4 1.17E-11 
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Pathway enrichment analysis using Kyoto Encyclopedia of Genes and Genomes (KEGG) and 
manually curated pathways indicated that cellular processes that were significantly induced in 
SCFM2 relative to 7H9-ADC-Tween 80 were disproportionately dominated by pathways for 
amino acid catabolism (branched-chain amino acids [leucine, valine and isoleucine], arginine, 
lysine, proline, alanine) and central carbon metabolism as it relates to pyruvate, lactate, glutamate, 
acetoacetic acid, propionyl-CoA and acetyl-CoA. Downregulated genes in SCFM2 were mostly 
for amino acid biosynthesis [Figure 4B; Table 1; Tables S2A-D]. Despite noticeable changes in 
the GPL composition of the isolates grown in SCFM2 relative to 7H9-ADC-Tween 80 [Fig. 3], 
the transcript levels of GPL biosynthetic genes29 were not statistically different between the media 
for any of the isolates.  
Comparison of differentially expressed genes in Mmas 1239 grown in 20% CF sputum vs 7H9-
ADC-Tween 80 and SCFM2 vs 7H9-ADC-Tween 80 identified 49 genes expressed at a 
significantly higher level in both SCFM2 and 20% CF sputum and 17 genes expressed at a 
significantly lower level in both media [Figure 4C and Table S2F]. Many of these genes are 
identical to those listed in Table 1 or fall in the same functional categories (see Figure 4B and 
genes highlighted in bold letters in Table 1).  
Mmas 1239 genes differentially expressed in CF sputum but not in SCFM2 relative to 7H9-
ADC-Tween 80 or, vice versa, differentially expressed in SCFM2 but not in CF sputum relative 
to 7H9-ADC-Tween 80 (based on a ≥2 Log2 fold-change cut-off) are listed in Table S2G. For the 
most part, these genes followed the same trend in both media despite showing differences in their 
level of expression.  
Real-time PCR confirmed the Mmas 1239 RNAseq data for five differentially expressed genes 
of interest: MAB_2157 (a putative fatty acid desaturase), ahpD (MAB_4407c), bkdC 
(MAB_4916c), MAB_4742c and MAB_4743c [Figure S5].  
 
Growth characteristics of BCKADH and GPL-deficient Mmas knock-out mutants in SCFM2 -  
Transcriptional profiling and lipid analyses converging to indicate that branched-chain amino acids 
(BCAAs) are major drivers of the physiological reprogramming undergone by MABSC under 
conditions relevant to the CF airway, we next sought to determine the effect of disrupting 
genetically the production of GPLs (including leucinol-containing forms of these lipids) or the 
branched-chain keto acid dehydrogenase (BCKADH) enzyme on the growth of MABSC in culture 
media containing various concentrations of BCAAs. Deletion mutants in the bkdA-bkdB-bkdC and 
mmpL4b genes (the latter gene being required for GPL biosynthesis)29 were generated by 
recombineering in the reference strain Mmas CIP108297 [Figure S6A]. In complete SCFM2 
medium, which contains other carbon sources besides BCAAs (including lactate, glucose, mucin 
and, in this case, 0.25% Tween 80 to facilitate CFU counting), the two mutants replicated 
comparably to the wild-type (WT) strain, despite the GPL-deficient strain consistently reaching a 
slightly lower cell density [Figure S6B].  
To more precisely determine the response of the BCKADH knock-out to BCAA levels, we 
next compared the growth of this mutant to that of its WT parent in minimal medium containing 
different concentrations of the individual or mixed BCAAs. Whereas the growth of the WT strain 
generally increased with increasing concentrations of BCAAs in the medium (both in terms of 
growth rate and maximum cell density), the BCKADH mutant displayed dramatically (~ 10-fold) 
reduced growth at 1x BCAA and was on the contrary inhibited by high concentrations of BCAAs 
reflective of its limited ability to process this carbon source and of the toxic build-up of branched-
chain keto acids in the cells when BCAAs are the sole carbon source in the culture medium [Figure 
 13 
5A]. In line with this observation, the mutant also grew very poorly when leucine, isoleucine or 
valine were used as sole carbon sources whereas it grew similarly to the WT parent strain in the 
presence of glucose [Figure 5B]. Of the three BCAAs, leucine was the preferred carbon source for 





Figure 5: Growth characteristics of the BCKADH mutant in branched amino acid-containing media.  
The results presented are representative of two independent experiments using different culture batches 
(biological replicates). 
(A) Growth of WT Mmas CIP108297 and the BCKADH-deficient mutant in minimal medium containing 
either the concentration of BCAAs normally found in SCFM2 (1x) or 10- or 40-times this amount. Note 
the 10-fold difference in Y-axis scale between the WT and mutant strains.  
(B) Growth of WT Mmas CIP108297 and the BCKADH-deficient mutant in minimal medium containing 
0.2% glucose, 0.2% equimolar BCAA mix, or 0.2% of each of the individual BCAAs, valine, leucine and 
isoleucine. 
 
 In line with our observations made on clinical isolates from patients with CF, the production 
of the dominant leucinol-containing form of GPL [Figure 2C and 3B] was increased both in the 
WT and BCKADH mutant grown in complete SCFM2 medium relative to 7H9-ADC-Tween 80. 
This increase, however, was significantly more marked in the mutant strain (2.47-fold ± 0.14 in 
the mutant vs 1.46-fold ± 0.11 in the WT parent; averages and SD of biological triplicates).  
 
Virulence attenuation of MABSC grown in SCFM2 -  Since changes in the cell surface 
composition and overall metabolism of MABSC caused by the different growth conditions may 
have impacted the way the bacterium interacted with host cells, we next compared the uptake and 
intracellular replication of Mmas 1239 and Mmas 184 grown either in 7H9-ADC-Tween-80, 



















































SCFM2 or SCFM2 without mucin, in THP-1 monocyte-derived macrophages and A549 epithelial 
cells. Overall, while no significant difference in cellular uptake was noticeable between growth 
conditions, the isolates grown in SCFM2 (with or without mucin) showed decreased intracellular 
replication compared to 7H9-ADC-Tween-80-grown bacilli, especially in THP-1 cells [Figure 6].  
SCFM2-grown MABSC thus appears to be less prepared for intracellular survival, a finding that 
may be explained by the fact that MABSC bacilli growing in airway sputum, whether 
planktonically or within biofilms, are expected to be mainly extracellular.  
 
 
Figure 6: Uptake and intracellular replication of Mmas 1239 and Mmas 184 in human THP-1 
monocyte-derived macrophages (A) and A549 epithelial cells (B).  
Isolates were grown either in 7H9-ADC-Tween-80, SCFM2 complete medium or SCFM2 without mucin 
and used to infect the cells at a multiplicity of infection of 10. Data is shown as mean values + SD of 
triplicate wells. Mmas 1239 grown in 7H9-ADC-Tween-80 replicates significantly more after one or two 
days than the same isolate grown in SCFM2 with or without mucin in both cell types [asterisks denote 
statistical significance per Student’s t-test (p<0.05)]. Mmas184 grown in 7H9-ADC-Tween-80 replicates 
significantly more than the same isolate grown in SCFM2 with or without mucin in THP-1 cells after one 
or two days, and in A549 cells after 2 days. The results presented are representative of two independent 
experiments. 
 
Comparative antibiotic susceptibility profile of MABSC clinical isolates grown in SCFM2 
versus cation-adjusted Mueller Hinton II - A current obstacle to the informed treatment of 
MABSC infections is the lack of correlation between in vivo and in vitro antibiotic susceptibility 
for most antibiotics with the exception of macrolides3. This limitation finally prompted us to 
determine if the susceptibility of isolates grown in SCFM2, which our results indicate are 
physiologically closely related to bacteria grown in CF sputum, was the same as the susceptibility 
measured in cation-adjusted Mueller-Hinton II broth. We tested a panel of fifteen clinically-
relevant antibiotics against fifteen (drug-susceptible and drug-resistant) MABSC reference strains 
and clinical isolates [Tables 2 and S3]. Furthermore, Minimum Inhibitory Concentrations (MICs) 
for three strains were tested both in complete SCFM2 medium and in SCFM2 devoid of mucin to 
determine the impact of mucin on MICs [Table 2]. Overall, MIC values measured in Mueller-
Hinton II broth and SCFM2 without mucin were very consistent, differing by two-fold or less 
which is deemed within the margin of experimental error and culture-to-culture variability. There 
were also very few instances of greater than 4-fold increases in MIC values in complete SCFM2 
relative to SCFM2 without mucin [Table 2]. As this was not an antibiotic-specific trend but rather 
isolated, strain-dependent, instances of varied susceptibility, we conclude that drug susceptibility 
determination in SCFM2 (with or without mucin) as described herein is unlikely to be more 

































1239 SCFM2 w/o mucin
1239 7H9 ADC Tw-80
184 SCFM2
184 SCFM2 w/o mucin









Table 2: MIC values against Mabs and Mmas reference strains and clinical isolates in cation-adjusted Mueller Hinton II broth, 
complete SCFM2 and SCFM2 devoid of mucin. 
MIC values are in µg/mL. Greater than 4-fold changes in MIC values between complete SCFM2 medium and SCFM2 without mucin 
or cation-adjusted Mueller Hinton II broth are highlighted in green. nd, not determined. MIC determinations were performed on two to 
three independent culture batches. MICs in complete SCFM2 medium for each isolate essentially focused on antibiotics with MICs < 



































Amikacin 16 64 8 64 nd 64 32 64 64 128 64 32 16 256 >256 
Apramycin  32 nd 32 4 8 4 2 8 1 2 1 4 2 2 1 
Azithromycin >160 nd >160 1.25 10 2.5 >160 nd >160 1.25 2.5 >160 >160 2.5 2.5 
Clarithromycin 160 nd 160 0.08 0.64 0.16 >160 nd >160 0.16 0.32 80 40 0.16 0.32 
Erythromycin >256 nd >256 8 40 8 >256 nd >256 2 8 >256 >256 8 4 
Kanamycin 8-16 32 8 8 16 8 16 16 8 32 64 32 32 16 32 
Ethambutol 160 nd 80 160 nd 160 320 nd 320 320 320 160 320 160 320 
Rifampicin >320 nd >320 >320 nd >320 >320 nd >320 >320 >320 >320 >320 >320 >320 
Streptomycin 128 128 64 8 8 4 32 128 64 256 128 128 128 >256 >256 
Cefoxitin 100 50 50 50 50 50 50 50 100 25 100 100 100 25 50 
Tobramycin 64 128 32 16 128 16 128 nd 64 >256 >256 64 64 >256 256 
Linezolid 32 128 64 8 128 16 4 32 4 8 16 8 16 8 16 
Tetracycline >160 nd >160 20 40 20 nd nd nd >160 >160 >160 >160 >160 >160 
Imipenem 64 nd 64 128 64 64 64 nd 128 nd nd 256 >256 32 64 







The results presented herein indicate that, despite not fully recapitulating all of the nutritional 
complexity and variety of stresses present in CF sputum, SCFM2 is clearly a closer proxy of actual 
CF sputum than 7H9-ADC-Tween 80 both in terms of transcriptional profile and surface lipid 
composition. Gene expression profiling and cell envelope analyses of four clustered and non-
clustered Mmas and Mabs isolates unambiguously pointed to amino acids, particularly lysine, 
alanine, proline, arginine and BCAAs being significant sources of carbon and energy for MABSC 
in both CF sputum and SCFM2, and to MABSC undergoing important cell surface and metabolic 
reprogramming in order to adapt to this particular nutritional environment. In this respect, our 
RNA-seq results confirm previous observations made by Miranda Caso-Luengo and collaborators 
on the initial transcriptional response of Mabs ATCC 19977 precultured in 7H9-ADC-Tween-80 
to a short-pulse (3-hour) exposure to SCFM230 (despite the mis-annotation in this earlier study of 
the BCKADH gene cluster as encoding a pyruvate dehydrogenase complex). bkdA, bkdB and bkdC, 
and other genes related to the catabolism of BCAAs, were among the most induced in SCFM2 and 
CF sputum relative to 7H9-ADC-Tween 80 [Table 1]. The requirement of BCKADH for optimal 
growth in BCAA-containing medium was further obvious from the dramatically reduced 
replication of a bkdA-bkdB-bkdC Mmas deletion mutant compared to its WT parent in minimal 
medium containing BCAAs as sole carbon sources [Figure 5].  
Other important changes undergone by MABSC exposed to the nutritional environment of the 
CF airway concerned their surface GPLs. The analysis of the GPL content of SCFM2- and CF 
sputum-grown MABSC compared to 7H9-ADC-Tween 80-grown bacilli indeed pointed to two 
significant alterations in the GPL composition of the CF media-grown cells: First was a sharp 
increase in the production of an as yet unknown form of diglycosylated GPL in which the 
branched-chain amino alcohol, leucinol, replaced the canonical alaninol at the C-terminus of the 
peptidyl moiety. Second was an increase in the ratio of triglycosylated to diglycosylated GPLs. 
The leucinol form of GPL represented >20% of GPLs in SCFM2-grown Mmas 604 and 1239 cells 
and ~ 10% of total GPLs in CF sputum-grown Mmas 1239 [Figure 3B]. Interestingly, its 
production was significantly more pronounced in Mmas cells deficient in BCKADH activity 
suggestive of the increased incorporation of leucine/leucinol into GPLs when the cells cannot 
efficiently metabolize leucine as a carbon source. Of particular interest was also the observation 
that the accumulation of both the triglycosylated and leucinol-containing forms of GPLs is strongly 
stimulated by the presence of mucin in the culture medium [Figure 3]. This finding points to host 
mucin being an important modulator of the cell surface properties of MABSC in the course of 
infection and is reminiscent of the recent observation that mucin-associated glycans control the 
surface properties and the secretion of a broad array of virulence factors in another prominent 
pathogen of the CF lung, P. aeruginosa28.  
The fact that these changes in GPL composition of all SCFM2-grown isolates did not reflect 
in the transcript levels of the gene responsible for the addition of the second rhamnosyl residue 
(gtf3; MAB_4112c) or those responsible for the synthesis of the peptidic moiety of GPLs (mps1 
and mps2)29 indicates that these changes in the cell surface properties of MABSC under CF growth 
conditions are independent of transcriptional regulation. In the case of the leucinol moiety, it is 
possible that the same Mps2 enzyme catalyzes the incorporation of alaninol, valinol and leucinol 
in GPL, with its activity towards producing leucinol- vs valinol- or alaninol-containing forms of 
these glycolipids being solely dictated by amino acid availability in the culture medium.  
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The biological significance of these alterations in the surface GPLs of the bacterium is 
currently unknown. The comparable growth rate of a WT and GPL-deficient Mmas mutant in 
SCFM2 [Figure S6B] does not support a predominant role for leucinol-containing GPLs in 
alleviating the potential stress caused by the intracellular accumulation of branched-chain amino 
keto acids when MABSC switches to BCAAs as major carbon sources during infection. Given the 
abundance of GPLs at the cell surface, it is possible however that BCAA-derived GPLs alter the 
interactions of MABSC with host cells, although not reflected in the THP-1 and A549 infection 
models used in this study. Alternatively or in addition, leucinol-containing GPLs could serve as a 
leucine storage since leucine appears to be one of MABSC’s preferred amino acid-derived carbon 
sources [Figure 5B]. Besides increasing the polarity of the cell surface, the physiological 
significance of an increased tri- to di-glycosylated GPL ratio is also not clearly understood. The 
comparable uptake and replication rates of MABSC grown in SCFM2 with or without mucin in 
THP-1 and A549 cells excludes a major role for tri-glycosylated GPLs in cell invasion and 
intracellular persistence. 
Cell infection studies indicated that SCFM2-grown bacteria seem to be less prepared to 
intracellular growth, particularly inside macrophages, compared to those grown in 7H9-ADC-
Tween-80. We tentatively attribute this result to the fact that MABSC bacilli located in airway 
sputum are expected to mainly reside extracellularly, whether growing planktonically or within 
biofilms. 
Another unexpected finding of our study was the absence of significant differences in the drug 
susceptibility profiles of MABSC isolates planktonically-grown in cation-adjusted Mueller Hinton 
II broth and in SCFM2 with or without mucin despite noticeable differences in their outer 
membrane composition. This result indicates that antibiotic susceptibility testing in SCFM2, 
despite being a closer mimic of the conditions encountered in CF sputum, is unlikely to be more 
predictive of clinical outcome than the current recommended CLSI protocol. The situation could 
be different, however, under biofilm-forming conditions where antibiotic tolerance is expected to 
vary with the nature of the biofilms formed in the different growth media31.  
Collectively, the studies reported herein yield significant new knowledge about the cell 
envelope composition and physiological changes undergone by MABSC upon adaptation to the 
nutritional changes imposed by growth in CF airway sputum. This work further lays the 
groundwork for future studies aimed at studying how MABSC grown in this environment responds 
to various host factors (e.g., different mucins) and host-relevant stresses (e.g., pH acidification, 
decrease in oxygen tension, nitrosative stress, influx of neutrophils, antibiotic treatment, etc.). In 
this regard, it will be interesting to determine whether any specific responses distinguish clustered 
versus non-clustered MABSC isolates that could account for the global expansion and worse 





Bacterial strains and culture conditions - Reference strains Mabs ATCC 19977 and Mmas CIP 
108297 were obtained from the ATCC and CIP collections, respectively. Clinical isolates from CF 
patients were from the Papworth University Hospital in Cambridge, UK.  
Strains were grown in Middlebrook 7H9 (BD Biosciences) supplemented with 0.5% glycerol and 
10% albumin-dextrose-catalase (ADC); in SCFM213; in minimal M63 medium supplemented with 
1 mM MgSO4, 0.05% tyloxapol, and 0.2% glucose; in M63 medium supplemented with 1 mM 
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MgSO4, 0.05% tyloxapol and 10% or 20% CF sputum; or in minimal medium (50 mM MOPS, 
0.085% NaCl, 50 µM FeCl3, 0.59 µM MnSO4, 3.5 µM ZnSO4, 4.5 µM CaCl2, 20 mM Asn, 1.6 
mM MgSO4, 2.5 mM Na2HPO4/KH2PO4, 0.05% tyloxapol, pH 7) containing different 
concentrations of glucose or BCAAs. See Supporting Text S1 for further details about the CF 
sputum medium preparation.  
 
Lipid, sugar, mycolic acids and fatty acid analyses – Detailed preparation and analytical 
procedures for lipids (including GPLs), mycolic acids, fatty acids and sugars are provided in the 
Supporting Text S1. 
 
Generation of mmpL4b and BCKADH knockout mutants of Mmas CIP 108297 – Knock-out 
mutants were generated by allelic replacement using a recombineering approach as detailed in the 
Supporting Text S1.  
 
Cell infections - Adenocarcinomic human alveolar basal epithelial A549 cells and acute monocytic 
leukemia monocyte-derived THP-1 cells were infected with Mmas 1239 and Mmas 184 isolates 
grown in different culture media at a multiplicity of infection (MOI) of 10 as described in the 
Supporting text S1.  
 
RNA extraction, RNA-seq sample preparation and qRT-PCR - RNA extraction with the Direct-
zol™ RNA Miniprep kit (Zymo Research), reverse transcription reactions using the Superscript 
IV First-Strand Synthesis System (Thermo Fisher) and qRT-PCRs using the SYBR Green PCR 
Master Mix (Sigma-Aldrich) were conducted as per the manufacturers’ protocols and analyzed on 
a CFX96 real-time PCR machine (Biorad). Details of the RNA-seq sample preparation and data 
analysis are provided in the Supporting Text S1. Libraries were sequenced using single-end or 
pair-end reads on an Illumina NextSeq instrument using the high-output 75 cycles or mid-output 
150 cycles.  
 
Data Availability - The sequencing data described in this publication have been submitted to the 
NCBI gene expression omnibus (GEO) under BioProject # PRJNA602697. 
 
Supporting Information 
Supporting methods, growth curves, MIC determinations against a panel of clinical isolates, cell 
envelope analyses, and RNA-sequencing analyses; evidence of gene disruption at the BCKADH 
and mmpL4b loci of Mmas CIP 108297. 
This information is available free of charge on the ACS Publications website.  
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